We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
25 November 2020
On 29 October 2020 Justice Manson of the Federal Court ordered the minister of health to issue a notice of compliance (NOC) to Fresenius Kabi for IDACIO (adalimumab), a biosimilar of AbbVie's HUMIRA.(1)
The minister of health had completed its review of Fresenius Kabi's new drug submission for IDACIO; the only outstanding issue was whether Fresenius Kabi had addressed the patents listed on the Patent Register in respect of HUMIRA.
Fresenius Kabi and AbbVie had entered into a licensing agreement including for the listed patents and AbbVie provided the minister of health with the following consent:
Pursuant to s. 7(2) of the Patented Medicines (Notice of Compliance Regulations), and solely for the purpose of these Regulations, AbbVie… herby consents to the making, constructing, and, on and after February 15, 2021, to the using and selling in Canada by Fresenius Kabi Canada Ltd, of IDACIO.
Subsection 7(2) of the regulations exempts a submission from its effects if "the Minister has been provided with evidence from the owner of the patent of their consent to the making, constructing, using or selling of the drug in Canada by the second person".
The minister of health considered AbbVie's consent to be effective only as of 15 February 2021, because in contrast to the activities permitted by an NOC, which allows 'selling' and 'advertising', the consent to only 'making' and 'constructing' would not meet the requirements of Subsection 7(2) of the regulations. The minister also read the word 'or' in Subsection 7(2) conjunctively, requiring unequivocal consent for all four activities.
Fresenius Kabi sought judicial review of the minister's refusal to issue an NOC until 15 February 2021.
Manson held that the minister had been unreasonable in refusing to grant the NOC, including on the basis that he viewed AbbVie's consent as "unequivocal consent to all four activities in subsection 7(2) of the NOC Regulations. The temporal nature of the consent does not render it ineffective". Manson noted that AbbVie did not object to immediate issuance of an NOC and any patent infringement issues between Fresenius Kabi and AbbVie are resolved by way of the licensing agreement. Manson also held that the minister had erred in her analysis of the text of Subsection 7(2) of the regulations and her interpretation of the disjunctive, but inclusive 'or'.
Given that Health Canada had completed its examination of the IDACIO submission, and the sole outstanding issue was the requirement of consent under Subsection 7(2) of the regulations, Manson held that there was no useful purpose in remitting the issue back to the minister of health. As such, he ordered the minister to issue the NOC.
The NOC issued for IDACIO on 30 October 2020. The minister of health may appeal as of right.
For further information on this topic please contact Urszula Wojtyra at Smart & Biggar by telephone (+1 416 593 5514) or email (firstname.lastname@example.org). The Smart & Biggar website can be accessed at www.smart-biggar.ca.
(1) Fresenius Kabi v Minister of Health, 2020 FC 1013.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.